Tag Archives: NASDAQ:LGND

Stephens Believes Ligand Pharma (NASDAQ: LGND) Still Has Room to Grow

In a report released yesterday, Drew Jones from Stephens reiterated a Buy rating on Ligand Pharma (NASDAQ: LGND), with a price target of $248. The company’s shares closed yesterday at $247.02, close to its 52-week high of $254.24. According to

Analysts Are Bullish on These Healthcare Stocks: LGND, CARA

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ligand Pharma (NASDAQ: LGND), Cara Therapeutics (NASDAQ: CARA) and Keryx Biopharma (NASDAQ: KERX) with bullish sentiments. Ligand Pharma (LGND) H.C. Wainwright analyst

H.C. Wainwright Sticks to Its Buy Rating for Ligand Pharma

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Ligand Pharma (NASDAQ: LGND), with a price target of $182. The company’s shares closed yesterday at $157.28. According to TipRanks.com, Pantginis has 0 stars on

H.C. Wainwright Maintains Their Buy Rating on Ligand Pharma

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Ligand Pharma (NASDAQ: LGND) today and set a price target of $170. The company’s shares closed yesterday at $159.81, close to its 52-week high of $170.30. Pantginis wrote: “Kyprolis Beats;

Analysts Conflicted on These Healthcare Names: Ligand Pharma (NASDAQ: LGND), Amedica (NASDAQ: AMDA) and Amgen Inc (NASDAQ: AMGN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ligand Pharma (NASDAQ: LGND), Amedica (NASDAQ: AMDA) and Amgen Inc (NASDAQ: AMGN). Ligand Pharma (NASDAQ: LGND) H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating

Analysts Conflicted on These Healthcare Names: Ligand Pharma (NASDAQ: LGND), Strongbridge Biopharma Plc (NASDAQ: SBBP) and DENTSPLY SIRONA Inc (NASDAQ: XRAY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ligand Pharma (NASDAQ: LGND), Strongbridge Biopharma Plc (NASDAQ: SBBP) and DENTSPLY SIRONA Inc (NASDAQ: XRAY). Ligand Pharma (NASDAQ: LGND) In a report released today, Joseph